Emily is a former editorial intern at Spectrum and a graduate student in New York University’s Science, Health & Environmental Reporting Program. Previously, Emily worked on aging research in Boston, Massachusetts. She has a B.A. in chemistry from Williams College in Williamstown, Massachusetts.
Emily Harris
Former news intern
Spectrum
From this contributor
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Prenatal exposures; Angelman trial suspension; autistic adult well-being
By
Emily Harris
17 July 2023 | 4 min read
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Modified MRI; father findings
By
Emily Harris
22 June 2023 | 4 min read
Null and Noteworthy: Reinforcing rigor; medication medley
This month’s newsletter highlights findings on the use of three medication types during pregnancy.
Null and Noteworthy: Reinforcing rigor; medication medley
By
Emily Harris
14 December 2022 | 4 min read
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
By
Emily Harris
10 November 2022 | 5 min read
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
By
Emily Harris
13 October 2022 | 5 min read
Explore more from The Transmitter
Remembering GABA pioneer Edward Kravitz
The biochemist, who died last month at age 92, was part of the first neurobiology department in the world and showed that gamma-aminobutyric acid is inhibitory.
Remembering GABA pioneer Edward Kravitz
The biochemist, who died last month at age 92, was part of the first neurobiology department in the world and showed that gamma-aminobutyric acid is inhibitory.
By
Claudia López Lloreda
24 October 2025 | 9 min listen
Protein tug-of-war controls pace of synaptic development, sets human brains apart
Human-specific duplicates of SRGAP2 prolong cortical development by manipulating SYNGAP, an autism-linked protein that slows synaptic growth.
Protein tug-of-war controls pace of synaptic development, sets human brains apart
Human-specific duplicates of SRGAP2 prolong cortical development by manipulating SYNGAP, an autism-linked protein that slows synaptic growth.
By
Holly Barker
23 October 2025 | 9 min listen
Neurons tune electron transport chain to survive onslaught of noxious stimuli
Nociceptors tamp down the production of reactive oxygen species in response to heat, chemical irritants or toxins.
Neurons tune electron transport chain to survive onslaught of noxious stimuli
Nociceptors tamp down the production of reactive oxygen species in response to heat, chemical irritants or toxins.
By
Viviane Callier
22 October 2025 | 5 min listen